Suppression of ribosomal protein RPS6KB1 by Nexrutine increases sensitivity of prostate tumors to radiation
Radiation therapy (XRT) is a standard treatment for prostate cancer (PCa). Although dose escalation increases local control, toxicity hampers further escalation. Broader improvement will be possible by the addition of adjuvant therapies, which can synergize with radiation and thus improve efficacy. We have identified a natural compound (Nexrutine, Nx) that inhibits the survival and growth of PCa cells in combination with radiation. Combination studies demonstrated strong interaction between Nx and radiation both in vitro in multiple PCa cell lines and in the Transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Source: Cancer Letters - Category: Cancer & Oncology Authors: Suleman S. Hussain, Shih-Bo Huang, Roble G. Bedolla, Paul Rivas, Joseph W. Basler, Gregory P. Swanson, Tim Hui-Ming Huang, Ganesh Narayanasamy, Nikos Papanikolaou, Hiroshi Miyamoto, I-Tien Yeh, Robert L. Reddick, Brad H. Pollock, Rita Ghosh, Addanki P. Ku Tags: Original Articles Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Prostate Cancer | Radiation Therapy | Study | Toxicology